BBIO BridgeBio Pharma Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 BridgeBio Pharma to Participate in May Investor Events

   PALO ALTO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:

   • Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel, Virtual: Wednesday, May 18^th at 2:30 pm ET
   • H. C. Wainwright Global Investment Conference, Virtual: Tuesday, May 24^th at 7:00 am ET
   • UBS Global Healthcare Conference, New York, NY: Tuesday, May 24^th at 11:30 am ET
   • J. P. Morgan West Coast Investor Day, San Francisco, CA: Tuesday, May 24^th at 12:00 pm ET

   To access more details on BridgeBio's presentations, please visit…

   View Full Article
2. 13 May 2022 BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years

   -Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million
   

   -Secured a two-year extension of interest-only period on its existing senior secured credit facility

   PALO ALTO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has entered into a definitive agreement with an undisclosed purchaser to sell its PRV for $110 million.

   The Company received the voucher in February 2021 under a U.S. Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases…

   View Full Article
3. 12 May 2022 BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

   - BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties
   

   -SHP2 inhibitor deal expands earlier agreement between BridgeBio and Bristol Myers Squibb to study BBP-398 in combination with OPDIVO® (nivolumab) in advanced solid tumors with KRAS mutations 
     
   - BridgeBio will continue to lead its three current Phase 1 monotherapy and BBP-398 combination therapy trials with additional support from Bristol Myers Squibb; future clinical trials will be performed and funded by Bristol Myers Squibb 

   PALO ALTO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company…

   View Full Article
4. 10 May 2022 BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

   PALO ALTO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on Wednesday, May 11^th at 7:40 pm ET.
   

   To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

   About BridgeBio Pharma, Inc.
   BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage…

   View Full Article
5. 05 May 2022 BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

   –Completed sale to Sentynl Therapeutics of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection
   
   –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn
   
   –Released positive data from Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), which demonstrated a 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive …

   View Full Article